$NIKI

Niki BioSolutions (NASDAQ: NIKI) announced that its subsidiary DiamiR Biosciences received NYSDOH CLEP approval to expand its APOE Genotyping test to include urine, plasma, and dried blood spots. The test, which identifies genetic variants linked to Alzheimer’s risk, was previously approved for blood, buccal swab, saliva, and tissue. The expansion allows for more accessible testing, including at-home or point-of-care sample collection, and supports integrated genetic and biomarker workflows.

Niki BioSolutions (NASDAQ:NIKI) subsidiary DiamiR Biosciences will genotype plasma samples from the Bio-Hermes-002 Alzheimer’s study, using its approved APOE genotyping assay. The data will be integrated into the study’s dataset, aiding clinical trial design and risk assessment. Niki BioSolutions operates a CLIA-certified lab for genomic and biomarker testing.

Niki BioSolutions (NIKI) appointed Thomas Freeburg as CFO, effective September 1, 2026. Freeburg, 59, previously held CFO/CAO roles at Interpace Biosciences and SEC reporting roles at Coach and Scholastic. The appointment is under a two-year agreement, according to an SEC filing.

Niki BioSolutions, Inc. (NIKI) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers . On October 9, 2026, the Board of Directors (the “Board”) of Niki BioSolutions, Inc., a Delaware corporation (the “Company”), appointed Thomas Freeburg as the Chief

Niki BioSolutions (NIKI) launched a $1.396M ATM equity program with H.C. Wainwright as sales agent. The company can sell common stock at market prices, with a 3.0% placement fee. The program allows flexible equity financing and can be terminated at any time.

Niki BioSolutions, Inc. (NIKI) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry Into a Material Definitive Agreement. On October 9, 2026, Niki BioSolutions, Inc. (the “Company”), entered into an At the Market Offering Agreement, dated October 9, 2026, (the “ Sales Agreement ”), by and among the Company , H.C. Wainwright & Co., LLC (“ Wainwri

Niki BioSolutions, Inc. (NIKI) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. In connection with the previously announced merger transaction, Mr. Ian Huen and Alidad Mireskandari became the CEO and CO

Niki BioSolutions, Inc. filed a request with the SEC to withdraw its Form F-3 registration statement, initially submitted on January 16, 2026. The company is no longer a Foreign Private Issuer and has filed a Form S-3 for a previously described offering. No securities were sold under the withdrawn registration.

Niki BioSolutions, Inc. (APM) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. EX-3.2 3 ea029826201ex3-2.htm FORM OF BYLAWS FOR NIKI BIOSOLUTIONS, INC Exhibit 3.2 BY-LAWS OF NIKI BIOSOLUTIONS, INC. (THE “CORPORATION”) ARTICLE I OFFICES The registered office of Niki Biosolutions, Inc. (the “Corporation”) shall be in the State of Delaware. The Corporation als

Andean Precious Metals Corp. (TSX: APM, OTCQX: ANPMF) reported Q2 2026 production of 25,387 gold equivalent ounces, up 4% year over year, and 52,730 GEOs for the first half, up 15%. San Bartolome drove growth; Golden Queen was below prior quarter. The company deferred silver and gold inventory sales and said it had $204.1M liquid assets at Q1 end. Financial results are due Aug. 11.